免疫測定市場：タイプ別、技術別、機器別、サンプルタイプ別、検出モード別、応用分野別、エンドユーザー別、展開タイプ別-2025-2030年世界予測

免疫測定市場の2023年の市場規模は263億米ドルで、2024年には282億9,000万米ドル、CAGR 7.24%で成長し、2030年には429億米ドルに達すると予測されています。

イムノアッセイ市場は現代診断学の最前線に位置し、多様なバイオマーカーや病態の検出において優れた感度と特異性を提供しています。過去数十年にわたる技術革新により、イムノアッセイは臨床と研究の両分野で中心的な役割を果たすようになりました。

近年、この分野は技術の進歩と生物学的システムのより深い理解によって拡大してきました。新しい調査手法の統合は、従来の診断手法と急速に変化するヘルスケア業界の要求とのギャップを埋めるのに役立っています。最先端の研究と進化する規制環境はイムノアッセイの重要性をさらに際立たせ、疾病モニタリング、治療開発、臨床管理においてイムノアッセイは不可欠なものとなっています。

業界専門家は、この市場の成長の原動力は検出の質とアプリケーションの多様性の両方にあると強調します。従来の方法からより洗練された技術への進歩は、アッセイ設計、自動化、データ統合の大幅な改善によって強化されてきました。このような開発は、診断手順の効率を高めるだけでなく、より広範な科学的調査や臨床介入をサポートします。

免疫測定エコシステムを再定義する変革的変化

イムノアッセイセクターは、そのオペレーションのフレームワークと市場力学を再定義する変革的なシフトの最中にあります。革新的な技術が次々と登場する中、従来のマニュアルアッセイから堅牢な自動化プラットフォームへの移行は、診断技術の大きな進化を意味します。この転換により、所要時間が短縮され、再現性が向上し、臨床医や研究者がより正確でタイムリーな判断を下せるようになりました。

デジタルトランスフォーメーションとデータ分析の統合もまた、この状況を一変させました。高度なイメージング、機械学習アルゴリズム、リアルタイムモニタリングシステムは現在、複雑な生物学的マーカーを確実に捉え、正確に解釈するために、アッセイ機器と連動しています。このような技術の融合は、イムノアッセイの精度を高めるだけでなく、個別化医療から大規模疫学研究まで、その応用範囲を広げています。

技術的な向上と並行して、規制の変更と標準化への確実な推進が、アッセイの性能と信頼性の新たな基準を打ち立てた。強化された品質管理対策と厳格なコンプライアンス・プロトコルが普及し、イノベーションが研究コンセプトから主流の臨床ツールへとシームレスに移行することを保証しています。このようなシフトは総体として、ヘルスケアの需要への対応力を高め、将来の課題に俊敏かつ的確に対応するための準備を整えた市場を牽引しています。

イムノアッセイ分野における主要なセグメンテーションの洞察

免疫測定市場をより深く理解するためには、そのセグメンテーションに影響を与える様々な側面を探ることが重要です。まず、定性的免疫測定法と定量的免疫測定法では、個別化診断に役立つ性能とアプリケーションの違いが示されます。酵素免疫測定法、酵素結合免疫吸着測定法、蛍光免疫測定法、ラテラルフロー測定法、ラジオイムノアッセイ、そして信頼性の高いウェスタンブロットを含む様々なプラットフォームが、様々な臨床応用における感度と特異性のベンチマークとなっています。

続いて、機器に基づくセグメンテーションでは、分析装置とキット、バイオセンサー、マイクロ流体デバイス、マイクロプレート、PCRデバイス、試薬、ソフトウェアとサービスがそれぞれ明確な価値に貢献している包括的な状況が明らかになりました。特に試薬セグメントは、抗体、抗原、ブロッキング試薬、バッファーと標準物質、酵素、基質などのサブカテゴリーに分類され、アッセイの正確性と信頼性を確保する上で極めて重要な役割を担っています。これらの複雑な詳細を補完するのは、血液サンプル、唾液サンプル、組織サンプル、尿サンプルなどのサンプルタイプに基づくセグメンテーションであり、これらの検査で処理される臨床検体の多様性を垣間見ることができます。

分析結果は、化学発光法、比色法、蛍光法、放射性同位元素法を含む、結果の解釈の基本となる検出モードにまで及ぶ。アレルギー、自己免疫疾患、心臓病学、内分泌学、感染症学、腫瘍学、毒物学などの分野での展開を通じて、イムノアッセイの多面的な性質を浮き彫りにしています。

エンドユーザーに基づくセグメンテーションでは、委託研究機関、診断研究所、病院・診療所、製薬・バイオテクノロジー企業、研究機関などが、これらのアッセイの可能性を活用している状況が描かれています。最後に、導入タイプ別のセグメンテーションでは、ラボ検査とポイントオブケア検査の両方を統合するという二重のアプローチが再確認され、それによって免疫測定法が現代の臨床ワークフローにどのように組み込まれているかの全体像が示されます。市場セグメンテーションの各要素は、市場の現状と将来の可能性についての重要な洞察を提供し、このダイナミックな市場に関する多角的な理解によって戦略的な意思決定がなされることを保証するものです。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患と感染症の増加と早期診断の利点
    • 医薬品開発におけるマルチプレックス検出技術の新たな応用
    • ポイントオブケア検査キットの必要性が高まる
  • 抑制要因
    • 免疫測定機器の製品リコールに関する懸念
  • 機会
    • 政府の支援と資金の増加は、免疫測定技術の研究開発を促進します。
    • 免疫測定に関連する自動化機器の技術的進歩
  • 課題
    • サンプルの品質と試薬の性能のばらつきによるアッセイ検証の問題
• 市場セグメンテーション分析
  • 展開タイプ：免疫測定におけるPOC（Point of Care）の重要な優先
  • 応用分野：アレルギー診断における免疫測定の採用により、包括的な結果を迅速に得る
  • 技術：生物学的サンプル中のタンパク質、ペプチド、ホルモンを検出するためのELISAの利用
  • 機器：高いスループットと精度を保証する分析装置の幅広い用途
  • サンプルの種類：免疫測定における唾液サンプルの使用を増やし、迅速で自宅での検査を実現
  • 検出モード：感度と多重化機能の向上により蛍光検出の使用が増加している
  • エンドユーザー：病院やクリニックで、診断や患者のモニタリングに迅速かつ信頼性の高い結果を提供するためのアッセイの使用
  • タイプ：個別化医療への重点の高まりと腫瘍学の進歩により、定量免疫測定法の採用が促進される
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 免疫測定市場：タイプ別

• 定性免疫測定
• 定量免疫測定

第7章 免疫測定市場：技術別

• 酵素免疫測定
• 酵素免疫測定法
• 蛍光免疫測定
• ラテラルフローアッセイ
• ラジオイムノアッセイ
• ウェスタンブロット

第8章 免疫測定市場楽器別

• 分析装置とキット
• バイオセンサー
• マイクロ流体デバイス
• マイクロプレート
• PCRデバイス
• 試薬
  • 抗体
  • 抗原
  • ブロッキング試薬
  • バッファと標準
  • 酵素
  • 基質
• ソフトウェアとサービス

第9章 免疫測定市場サンプルタイプ別

• 血液サンプル
• 唾液サンプル
• 組織サンプル
• 尿サンプル

第10章 免疫測定市場検出モード別

• 化学発光
• 比色分析
• 蛍光測定
• 放射性同位元素

第11章 免疫測定市場アプリケーション分野別

• アレルギー
• 自己免疫疾患
• 心臓病学
• 内分泌学
• 感染症
• 腫瘍学
• 毒物学
  • 薬物検査
  • 環境試験

第12章 免疫測定市場：エンドユーザー別

• 契約調査機関
• 診断検査室
• 病院と診療所
• 製薬・バイオテクノロジー企業
• 調査機関

第13章 免疫測定市場展開タイプ別

• 臨床検査
• ポイントオブケアテスト

第14章 南北アメリカの免疫測定市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第15章 アジア太平洋地域の免疫測定市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第16章 欧州・中東・アフリカの免疫測定市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第17章 競合情勢

• 市場シェア分析, 2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Agilent Technologies Inc.
• Almac Group Limited
• ANP Technologies, Inc.
• Autobio Diagnostics Co., Ltd.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• BioLegend, Inc.
• bioMerieux S.A.
• Biosurfit SA
• Boditech Med Inc.
• Charles River Laboratories International, Inc.
• Danaher Corporation
• Diasorin S.p.A.
• Dynex Technologies, Inc.
• Epitope Diagnostics Inc.
• F. Hoffmann-La Roche Ltd.
• Fapon Biotech Inc.
• Gyros Protein Technologies AB by Mesa Laboratories, Inc.
• H.U. Group Holdings Inc.
• J. Mitra & Co. Pvt. Ltd.
• Kamiya Biomedical Company
• Koninklijke Philips N.V.
• Merck KGaA
• MiCo BioMed, Inc.
• NanoEntek
• Nanomix, Inc.
• OPKO Health, Inc.
• Promega Corporation
• QIAGEN N.V.
• Quanterix Corporation
• QuidelOrtho Corporation
• Randox Laboratories Ltd.
• Revvity, Inc.（Formarly PerkinElmer, Inc.）
• Sekisui Diagnostics, LLC
• Shenzhen Micropoint Biotechnologies Co., Ltd.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Siemens Healthineers AG
• Sysmex Corporation
• Tecan Trading AG
• Thermo Fisher Scientific Inc.
• Tosoh Corporation
• WAK-Chemie Medical GmbH
• Zoetis Inc.
• Zybio Inc.

LIST OF FIGURES

• FIGURE 1. IMMUNOASSAY MARKET MULTI-CURRENCY
• FIGURE 2. IMMUNOASSAY MARKET MULTI-LANGUAGE
• FIGURE 3. IMMUNOASSAY MARKET RESEARCH PROCESS
• FIGURE 4. IMMUNOASSAY MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL IMMUNOASSAY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL IMMUNOASSAY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL IMMUNOASSAY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2023 VS 2030 (%)
• FIGURE 19. GLOBAL IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
• FIGURE 21. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. GLOBAL IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2023 VS 2030 (%)
• FIGURE 23. GLOBAL IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 27. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 28. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 29. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 30. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 31. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 32. IMMUNOASSAY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 33. IMMUNOASSAY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. IMMUNOASSAY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL IMMUNOASSAY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. IMMUNOASSAY MARKET DYNAMICS
• TABLE 7. GLOBAL IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL IMMUNOASSAY MARKET SIZE, BY QUALITATIVE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL IMMUNOASSAY MARKET SIZE, BY QUANTITATIVE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENZYME IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL IMMUNOASSAY MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL IMMUNOASSAY MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL IMMUNOASSAY MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL IMMUNOASSAY MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL IMMUNOASSAY MARKET SIZE, BY ANALYZERS & KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL IMMUNOASSAY MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL IMMUNOASSAY MARKET SIZE, BY MICROFLUIDIC DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL IMMUNOASSAY MARKET SIZE, BY MICROPLATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL IMMUNOASSAY MARKET SIZE, BY PCR DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL IMMUNOASSAY MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL IMMUNOASSAY MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL IMMUNOASSAY MARKET SIZE, BY ANTIGENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOCKING REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL IMMUNOASSAY MARKET SIZE, BY BUFFERS & STANDARDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL IMMUNOASSAY MARKET SIZE, BY SUBSTRATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL IMMUNOASSAY MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL IMMUNOASSAY MARKET SIZE, BY SALIVA SAMPLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL IMMUNOASSAY MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL IMMUNOASSAY MARKET SIZE, BY URINE SAMPLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL IMMUNOASSAY MARKET SIZE, BY CHEMILUMINESCENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL IMMUNOASSAY MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL IMMUNOASSAY MARKET SIZE, BY FLUOROMETRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL IMMUNOASSAY MARKET SIZE, BY RADIOISOTOPIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL IMMUNOASSAY MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL IMMUNOASSAY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL IMMUNOASSAY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL IMMUNOASSAY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL IMMUNOASSAY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL IMMUNOASSAY MARKET SIZE, BY DRUG SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENVIRONMENTAL TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL IMMUNOASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 55. GLOBAL IMMUNOASSAY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 56. GLOBAL IMMUNOASSAY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 57. GLOBAL IMMUNOASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 58. GLOBAL IMMUNOASSAY MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 59. GLOBAL IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 60. GLOBAL IMMUNOASSAY MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 61. GLOBAL IMMUNOASSAY MARKET SIZE, BY POINT-OF-CARE TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 62. AMERICAS IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. AMERICAS IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 64. AMERICAS IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 65. AMERICAS IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 66. AMERICAS IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 67. AMERICAS IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 68. AMERICAS IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 69. AMERICAS IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 70. AMERICAS IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 71. AMERICAS IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 72. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 73. ARGENTINA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. ARGENTINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 75. ARGENTINA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 76. ARGENTINA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 77. ARGENTINA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 78. ARGENTINA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 79. ARGENTINA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 80. ARGENTINA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 81. ARGENTINA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 82. ARGENTINA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 83. BRAZIL IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. BRAZIL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 85. BRAZIL IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 86. BRAZIL IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 87. BRAZIL IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 88. BRAZIL IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 89. BRAZIL IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 90. BRAZIL IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 91. BRAZIL IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 92. BRAZIL IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 93. CANADA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. CANADA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. CANADA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 96. CANADA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 97. CANADA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 98. CANADA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 99. CANADA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 100. CANADA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. CANADA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 102. CANADA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 103. MEXICO IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. MEXICO IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 105. MEXICO IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 106. MEXICO IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 107. MEXICO IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 108. MEXICO IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 109. MEXICO IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 110. MEXICO IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 111. MEXICO IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 112. MEXICO IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 113. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 115. UNITED STATES IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 116. UNITED STATES IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 117. UNITED STATES IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 118. UNITED STATES IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 119. UNITED STATES IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 120. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 121. UNITED STATES IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 122. UNITED STATES IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 123. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 124. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 126. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 127. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 128. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 129. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 130. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 131. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 132. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 133. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 134. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 135. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 137. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 138. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 139. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 140. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 141. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 142. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 144. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 145. CHINA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. CHINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 147. CHINA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 148. CHINA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 149. CHINA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 150. CHINA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 151. CHINA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 152. CHINA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 153. CHINA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 154. CHINA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 155. INDIA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. INDIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 157. INDIA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 158. INDIA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 159. INDIA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 160. INDIA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 161. INDIA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 162. INDIA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 163. INDIA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 164. INDIA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 165. INDONESIA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. INDONESIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 167. INDONESIA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 168. INDONESIA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 169. INDONESIA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 170. INDONESIA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 171. INDONESIA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 172. INDONESIA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 173. INDONESIA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 174. INDONESIA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 175. JAPAN IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 176. JAPAN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 177. JAPAN IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 178. JAPAN IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 179. JAPAN IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 180. JAPAN IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 181. JAPAN IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 182. JAPAN IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 183. JAPAN IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 184. JAPAN IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 185. MALAYSIA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. MALAYSIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 187. MALAYSIA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 188. MALAYSIA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 189. MALAYSIA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 190. MALAYSIA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 191. MALAYSIA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 192. MALAYSIA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 193. MALAYSIA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 194. MALAYSIA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 195. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 197. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 198. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 199. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 200. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 201. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 202. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 203. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 204. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 205. SINGAPORE IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 206. SINGAPORE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 207. SINGAPORE IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 208. SINGAPORE IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 209. SINGAPORE IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 210. SINGAPORE IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 211. SINGAPORE IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 212. SINGAPORE IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 213. SINGAPORE IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 214. SINGAPORE IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 215. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 216. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 217. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 218. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 219. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 220. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 221. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 222. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 223. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 224. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 225. TAIWAN IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 226. TAIWAN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 227. TAIWAN IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 228. TAIWAN IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 229. TAIWAN IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 230. TAIWAN IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 231. TAIWAN IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 232. TAIWAN IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 233. TAIWAN IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 234. TAIWAN IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 235. THAILAND IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 236. THAILAND IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 237. THAILAND IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 238. THAILAND IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 239. THAILAND IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 240. THAILAND IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 241. THAILAND IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 242. THAILAND IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 243. THAILAND IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 244. THAILAND IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 245. VIETNAM IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 246. VIETNAM IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 247. VIETNAM IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 248. VIETNAM IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 249. VIETNAM IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 250. VIETNAM IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 251. VIETNAM IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 252. VIETNAM IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 253. VIETNAM IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 254. VIETNAM IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 255. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 256. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 257. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 258. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 259. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 260. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 261. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 262. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 263. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 264. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 265. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 266. DENMARK IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 267. DENMARK IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 268. DENMARK IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 269. DENMARK IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 270. DENMARK IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 271. DENMARK IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 272. DENMARK IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 273. DENMARK IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 274. DENMARK IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 275. DENMARK IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 276. EGYPT IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 277. EGYPT IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 278. EGYPT IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 279. EGYPT IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 280. EGYPT IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 281. EGYPT IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 282. EGYPT IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 283. EGYPT IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 284. EGYPT IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 285. EGYPT IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 286. FINLAND IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 287. FINLAND IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 288. FINLAND IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 289. FINLAND IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 290. FINLAND IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 291. FINLAND IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 292. FINLAND IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 293. FINLAND IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 294. FINLAND IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 295. FINLAND IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 296. FRANCE IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 297. FRANCE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 298. FRANCE IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 299. FRANCE IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 300. FRANCE IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 301. FRANCE IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 302. FRANCE IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 303. FRANCE IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 304. FRANCE IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 305. FRANCE IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 306. GERMANY IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 307. GERMANY IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 308. GERMANY IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 309. GERMANY IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 310. GERMANY IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 311. GERMANY IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 312. GERMANY IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 313. GERMANY IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 314. GERMANY IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 315. GERMANY IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 316. ISRAEL IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 317. ISRAEL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 318. ISRAEL IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 319. ISRAEL IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 320. ISRAEL IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 321. ISRAEL IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 322. ISRAEL IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 323. ISRAEL IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 324. ISRAEL IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 325. ISRAEL IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 326. ITALY IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 327. ITALY IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 328. ITALY IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 329. ITALY IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 330. ITALY IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 331. ITALY IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 332. ITALY IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 333. ITALY IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 334. ITALY IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 335. ITALY IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 336. NETHERLANDS IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 337. NETHERLANDS IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 338. NETHERLANDS IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 339. NETHERLANDS IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 340. NETHERLANDS IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 341. NETHERLANDS IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 342. NETHERLANDS IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 343. NETHERLANDS IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 344. NETHERLANDS IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 345. NETHERLANDS IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 346. NIGERIA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 347. NIGERIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 348. NIGERIA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 349. NIGERIA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 350. NIGERIA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 351. NIGERIA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 352. NIGERIA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 353. NIGERIA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 354. NIGERIA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 355. NIGERIA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 356. NORWAY IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 357. NORWAY IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 358. NORWAY IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 359. NORWAY IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 360. NORWAY IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 361. NORWAY IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 362. NORWAY IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 363. NORWAY IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 364. NORWAY IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 365. NORWAY IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 366. POLAND IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 367. POLAND IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 368. POLAND IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 369. POLAND IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 370. POLAND IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2030 (USD MILLION)
• TABLE 371. POLAND IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2030 (USD MILLION)
• TABLE 372. POLAND IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 373. POLAND IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2030 (USD MILLION)
• TABLE 374. POLAND IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 375. POLAND IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2030 (USD MILLION)
• TABLE 376. QATAR IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 377. QATAR IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 378. QATAR IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 379. QATAR IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 380. QATAR IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2

The Immunoassay Market was valued at USD 26.30 billion in 2023 and is projected to grow to USD 28.29 billion in 2024, with a CAGR of 7.24%, reaching USD 42.90 billion by 2030.

The immunoassay market stands at the forefront of modern diagnostics, offering both superior sensitivity and specificity in detecting a wide array of biomarkers and disease states. Over the past decades, innovation has propelled immunoassays into a central role in both clinical and research settings, driven by the continuous quest for improved health outcomes and the urgent need for early disease detection.

In recent years, this field has expanded through technological advancements and a deeper understanding of biological systems. The integration of novel methodologies has helped bridge the gap between traditional diagnostic practices and the demands of a rapidly changing healthcare industry. Cutting-edge research and an evolving regulatory environment have further accentuated the importance of immunoassays, making them indispensable in disease monitoring, therapeutic development, and clinical management.

Industry experts highlight that the impetus for growth within this market stems from both the quality of detection and the versatility of applications. The progression from conventional methods to more refined techniques has been reinforced by significant improvements in assay design, automation, and data integration. Such developments not only enhance the efficiency of diagnostic procedures but also support a broader spectrum of scientific inquiries and clinical interventions.

Transformative Shifts Redefining the Immunoassay Ecosystem

The immunoassay sector is undergoing transformative shifts that are redefining its operational framework and market dynamics. With innovations continually emerging, the transition from traditional manual assays to robust, automated platforms marks a significant evolution in diagnostic technology. This shift has curtailed turnaround times and increased reproducibility, allowing clinicians and researchers to make more accurate and timely decisions.

Digital transformation and the integration of data analytics have also revolutionized the landscape. Advanced imaging, machine learning algorithms, and real-time monitoring systems now work in tandem with assay instruments to ensure that the complexity of biological markers is captured and interpreted accurately. This fusion of technology not only enhances the accuracy of immunoassays but also broadens their range of applications, from personalized medicine to large-scale epidemiological studies.

Parallel to technological enhancements, regulatory changes and a solid push toward standardization have collectively set a new benchmark for assay performance and reliability. Enhanced quality control measures and stringent compliance protocols are now more prevalent, ensuring that innovations are seamlessly transitioned from research concepts to mainstream clinical tools. These shifts collectively drive a market that is more responsive to healthcare demands and better prepared to meet future challenges with agility and precision.

Key Segmentation Insights Across the Immunoassay Spectrum

For a deeper understanding of the immunoassay market, it is critical to explore the various dimensions that influence its segmentation. The market is studied from multiple perspectives, beginning with the type of immunoassays where qualitative immunoassays and quantitative immunoassays illustrate differences in performance and application that are instrumental for personalized diagnostics. Equally important is the segmentation based on technology; a range of platforms including enzyme immunoassays, enzyme-linked immunosorbent assays, fluorescent immunoassays, lateral flow assays, radioimmunoassays, and the ever-reliable western blot serve as benchmarks for sensitivity and specificity in varied clinical applications.

Moving on, segmentation based on instruments reveals a comprehensive landscape where analyzers and kits, biosensors, microfluidic devices, microplates, PCR devices, reagents, and software and services each contribute distinct value. In particular, the reagent segment stands out as it is further analyzed into subcategories such as antibodies, antigens, blocking reagents, buffers and standards, enzymes, and substrates-all of which play pivotal roles in ensuring assay accuracy and reliability. Complementing these intricate details is the segmentation based on sample types where blood samples, saliva samples, tissue samples, and urine samples offer just a glimpse into the diversity of clinical specimens processed by these tests.

Analysis extends to detection modes that are fundamental to the interpretation of results, encompassing chemiluminescent, colorimetric, fluorometric, and radioisotopic techniques. Equally significant is the segmentation by application areas, which highlights the multi-faceted nature of immunoassays through their deployment in fields such as allergy, autoimmune diseases, cardiology, endocrinology, infectious diseases, oncology, and toxicology, with the latter including specialized segments like drug screening and environmental testing.

Diving deeper, the segmentation based on end users maps out a landscape where contract research organizations, diagnostic laboratories, hospitals and clinics, pharmaceutical and biotechnology companies, alongside research institutions, harness the potential of these assays. Finally, segmentation by deployment types reaffirms the dual approach of integrating both laboratory tests and point-of-care tests, thereby presenting a complete picture of how immunoassays are embedded into modern clinical workflows. Each segmentation element offers critical insights into the market's current state and future potential, ensuring that strategic decisions are informed by a multi-dimensional understanding of this dynamic space.

Based on Type, market is studied across Qualitative Immunoassays and Quantitative Immunoassays.

Based on Technology, market is studied across Enzyme Immunoassays, Enzyme-Linked Immunosorbent Assay, Fluorescent Immunoassay, Lateral Flow Assay, Radioimmunoassay, and Western Blot.

Based on Instruments, market is studied across Analyzers & Kits, Biosensors, Microfluidic Devices, Microplates, PCR Devices, Reagents, and Software & Services. The Reagents is further studied across Antibodies, Antigens, Blocking Reagents, Buffers & Standards, Enzymes, and Substrates.

Based on Sample Types, market is studied across Blood Samples, Saliva Samples, Tissue Samples, and Urine Samples.

Based on Detection Modes, market is studied across Chemiluminescent, Colorimetric, Fluorometric, and Radioisotopic.

Based on Application Areas, market is studied across Allergy, Autoimmune Diseases, Cardiology, Endocrinology, Infectious Diseases, Oncology, and Toxicology. The Toxicology is further studied across Drug Screening and Environmental Testing.

Based on End Users, market is studied across Contract Research Organizations, Diagnostic Laboratories, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Research Institutions.

Based on Deployment Types, market is studied across Laboratory Tests and Point-of-care Test.

Key Regional Insights Shaping Market Trends

The regional dynamics of the immunoassay market provide a nuanced understanding of its growth trajectory and operational challenges across diverse geographical landscapes. In the Americas, rapid technological adoption and substantial investments in healthcare infrastructure have led to significant advances in diagnostic capabilities. With a robust network of hospitals, research centers, and diagnostic laboratories, the region is positioned to harness the expanding applications of immunoassays effectively.

Within Europe, the Middle East, and Africa, a combination of stringent regulatory environments and increasing funding for healthcare innovations is driving progress. Regulatory frameworks in these regions are evolving to better accommodate emerging technologies, thereby fostering an ecosystem where immunoassays can flourish. Moreover, targeted initiatives for improving public health and disease management have further catalyzed the integration of advanced diagnostic tools.

The Asia-Pacific region stands out due to its rapid industrialization and consistent growth in healthcare expenditure, which have spurred the adoption of next-generation immunoassays. Diverse economies within this region contribute unique perspectives, but common threads such as a rising focus on early diagnosis, efficient sample processing, and cost-effective healthcare delivery converge to promote a competitive yet collaborative market environment. As such, each region contributes distinct insights that collectively drive the global advancement of immunoassay technologies, guiding market stakeholders toward a holistic understanding of regional opportunities and challenges.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Driving Innovation and Market Expansion

Several leading companies have carved out distinctive positions within the immunoassay market, leveraging innovation and operational expertise to meet evolving industry demands. Major names such as Abbott Laboratories and Agilent Technologies Inc. have been instrumental in advancing assay technologies with a focus on both reliability and efficiency. Companies like Almac Group Limited, ANP Technologies, Inc., and Autobio Diagnostics Co., Ltd. continue to introduce groundbreaking solutions that address a wide range of clinical applications.

Other significant contributors include Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, and BioLegend, Inc., all of which have strengthened their market presence through advanced product offerings and strategic collaborations. Moreover, bioMerieux S.A., Biosurfit SA, and Boditech Med Inc. have consistently pushed the envelope in assay precision and implementation. In addition, multinational giants such as Charles River Laboratories International, Inc. and Danaher Corporation have played a vital role in bolstering market growth through investment in research and innovation.

Further, companies like Diasorin S.p.A., Dynex Technologies, Inc., Epitope Diagnostics Inc., and F. Hoffmann-La Roche Ltd. have continued to lead by example, ensuring that their technological prowess translates into impactful clinical solutions. The list extends with Fapon Biotech Inc., Gyros Protein Technologies AB by Mesa Laboratories, Inc., H.U. Group Holdings Inc., and J. Mitra & Co. Pvt. Ltd. making significant contributions. Additional pioneers such as Kamiya Biomedical Company, Koninklijke Philips N.V., Merck KGaA, and MiCo BioMed, Inc. have also positioned themselves as key players.

Notably, further companies including NanoEntek, Nanomix, Inc., OPKO Health, Inc., Promega Corporation, QIAGEN N.V., Quanterix Corporation, and QuidelOrtho Corporation are continuously redefining industry standards. Contributions from Randox Laboratories Ltd., Revvity, Inc. (formerly PerkinElmer, Inc.), Sekisui Diagnostics, LLC, Shenzhen Micropoint Biotechnologies Co., Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Sysmex Corporation, Tecan Trading AG, Thermo Fisher Scientific Inc., Tosoh Corporation, WAK-Chemie Medical GmbH, Zoetis Inc., and Zybio Inc. further illustrate the collaborative and competitive dynamics that are driving innovation and market expansion in this space.

The report delves into recent significant developments in the Immunoassay Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies Inc., Almac Group Limited, ANP Technologies, Inc., Autobio Diagnostics Co., Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, BioLegend, Inc., bioMerieux S.A., Biosurfit SA, Boditech Med Inc., Charles River Laboratories International, Inc., Danaher Corporation, Diasorin S.p.A., Dynex Technologies, Inc., Epitope Diagnostics Inc., F. Hoffmann-La Roche Ltd., Fapon Biotech Inc., Gyros Protein Technologies AB by Mesa Laboratories, Inc., H.U. Group Holdings Inc., J. Mitra & Co. Pvt. Ltd., Kamiya Biomedical Company, Koninklijke Philips N.V., Merck KGaA, MiCo BioMed, Inc., NanoEntek, Nanomix, Inc., OPKO Health, Inc., Promega Corporation, QIAGEN N.V., Quanterix Corporation, QuidelOrtho Corporation, Randox Laboratories Ltd., Revvity, Inc. (Formarly PerkinElmer, Inc.), Sekisui Diagnostics, LLC, Shenzhen Micropoint Biotechnologies Co., Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Sysmex Corporation, Tecan Trading AG, Thermo Fisher Scientific Inc., Tosoh Corporation, WAK-Chemie Medical GmbH, Zoetis Inc., and Zybio Inc.. Actionable Recommendations for Industry Leaders to Bolster Market Position

Industry leaders must adopt a multi-pronged strategy to capitalize on the continuous advancements in the immunoassay sector. A deep dive into emerging technology trends and a commitment to leveraging digital transformation will be crucial in enhancing diagnostic capabilities. Decision makers should focus on integrating automated platforms with advanced data analytics to streamline assay operations, thus contributing to reduced turnaround times and enhanced diagnostic precision.

Investing in comprehensive R&D and fostering collaborations across academia and industry can further drive innovation. Such partnerships offer an opportunity to merge foundational scientific research with commercial-scale manufacturing, ultimately enabling the development of next-generation immunoassays. Leaders should also consider direct engagement with regulatory bodies to advocate for faster approval pathways and more coherent compliance frameworks. This can help mitigate the challenges associated with the rapid introduction of new technologies and secure a competitive edge in an evolving market.

Strategically aligning business models with market segmentation insights-whether by type, technology, instruments, sample types, detection modes, application areas, end users, or deployment types-ensures that product development fits precisely into unmet needs. In parallel, geographic diversification remains a potent strategy for mitigating risks and tapping into varying regional growth drivers. By understanding local market nuances and tailoring products to regional demands, companies can better navigate through competitive pressures while optimizing their market footprint.

Finally, implementing robust post-market surveillance and feedback mechanisms is essential to ensure continuous improvement. By actively monitoring product performance and customer satisfaction, industry leaders gain invaluable insights that allow for iterative enhancements, thus cementing their positions as innovators in the immunoassay arena.

Conclusion: Navigating the Future of Immunoassay Innovation

The immunoassay market is on an upward trajectory characterized by technological refinement, strategic segmentation, and dynamic regional influences. As the industry continues its march towards enhanced diagnostic accuracy and efficient testing solutions, stakeholders are presented with unprecedented opportunities for growth and innovation. The integration of automated systems, cutting-edge detection methods, and versatile instrumentation has substantially transformed traditional practices. This evolution underscores the importance of agility and forward-thinking strategies in addressing both current and future challenges.

At its core, the journey within the immunoassay landscape is one of continuous adaptation and proactive engagement. By staying abreast of emerging trends and harnessing the power of digital transformation, market players can better align their offerings with the evolving needs of healthcare providers and patients alike. The path forward not only necessitates technological investment but also a renewed focus on collaboration, regulatory diligence, and targeted market segmentation.

In summary, the future of immunoassays is bright, with ample opportunities for those willing to innovate and invest in robust diagnostic frameworks. The evolving market, driven by transformative shifts and strategic insights, promises to deliver enhanced patient outcomes and drive significant advancements in both clinical and research domains.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising chronic and infectious diseases and benefits of early diagnosis
    • 5.1.1.2. Emerging application of multiplex detection immunoassay technique in drug development
    • 5.1.1.3. Increasing need for point-of-care immunoassay testing kits
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with product recall for immunoassay instruments
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing government support and funding fosters research and development in immunoassay technologies
    • 5.1.3.2. Technological advancements in the automated equipment associated with immunoassay
  • 5.1.4. Challenges
    • 5.1.4.1. Issues with assay validation due to variations in sample quality and reagent performance
• 5.2. Market Segmentation Analysis
  • 5.2.1. Deployment Type: Significant preference for point of care point of care in immunoassay
  • 5.2.2. Application Areas: Adoption of immunoassay in allergy diagnostics to obtain comprehensive results quickly
  • 5.2.3. Technology: Utilization of ELISA for detecting proteins, peptides, and hormones in biological samples
  • 5.2.4. Instruments: Wide utility of analyzer to ensure high throughput and accuracy
  • 5.2.5. Sample Types: Increasing the use of saliva samples in immunoassay for rapid and at-home testing
  • 5.2.6. Detection Modes: Rising usage of fluorometric detection due to its enhanced sensitivity and multiplexing capabilities
  • 5.2.7. End Users: Usage of assays in hospitals & clinics to provide swift and reliable results for diagnostics and patient monitoring
  • 5.2.8. Type: Growing emphasis on personalized medicine and advancements in oncology drives the adoption of quantitative immunoassays
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Immunoassay Market, by Type

• 6.1. Introduction
• 6.2. Qualitative Immunoassays
• 6.3. Quantitative Immunoassays

7. Immunoassay Market, by Technology

• 7.1. Introduction
• 7.2. Enzyme Immunoassays
• 7.3. Enzyme-Linked Immunosorbent Assay
• 7.4. Fluorescent Immunoassay
• 7.5. Lateral Flow Assay
• 7.6. Radioimmunoassay
• 7.7. Western Blot

8. Immunoassay Market, by Instruments

• 8.1. Introduction
• 8.2. Analyzers & Kits
• 8.3. Biosensors
• 8.4. Microfluidic Devices
• 8.5. Microplates
• 8.6. PCR Devices
• 8.7. Reagents
  • 8.7.1. Antibodies
  • 8.7.2. Antigens
  • 8.7.3. Blocking Reagents
  • 8.7.4. Buffers & Standards
  • 8.7.5. Enzymes
  • 8.7.6. Substrates
• 8.8. Software & Services

9. Immunoassay Market, by Sample Types

• 9.1. Introduction
• 9.2. Blood Samples
• 9.3. Saliva Samples
• 9.4. Tissue Samples
• 9.5. Urine Samples

10. Immunoassay Market, by Detection Modes

• 10.1. Introduction
• 10.2. Chemiluminescent
• 10.3. Colorimetric
• 10.4. Fluorometric
• 10.5. Radioisotopic

11. Immunoassay Market, by Application Areas

• 11.1. Introduction
• 11.2. Allergy
• 11.3. Autoimmune Diseases
• 11.4. Cardiology
• 11.5. Endocrinology
• 11.6. Infectious Diseases
• 11.7. Oncology
• 11.8. Toxicology
  • 11.8.1. Drug Screening
  • 11.8.2. Environmental Testing

12. Immunoassay Market, by End Users

• 12.1. Introduction
• 12.2. Contract Research Organizations
• 12.3. Diagnostic Laboratories
• 12.4. Hospitals & Clinics
• 12.5. Pharmaceutical & Biotechnology Companies
• 12.6. Research Institutions

13. Immunoassay Market, by Deployment Types

• 13.1. Introduction
• 13.2. Laboratory Tests
• 13.3. Point-of-care Test

14. Americas Immunoassay Market

• 14.1. Introduction
• 14.2. Argentina
• 14.3. Brazil
• 14.4. Canada
• 14.5. Mexico
• 14.6. United States

15. Asia-Pacific Immunoassay Market

• 15.1. Introduction
• 15.2. Australia
• 15.3. China
• 15.4. India
• 15.5. Indonesia
• 15.6. Japan
• 15.7. Malaysia
• 15.8. Philippines
• 15.9. Singapore
• 15.10. South Korea
• 15.11. Taiwan
• 15.12. Thailand
• 15.13. Vietnam

16. Europe, Middle East & Africa Immunoassay Market

• 16.1. Introduction
• 16.2. Denmark
• 16.3. Egypt
• 16.4. Finland
• 16.5. France
• 16.6. Germany
• 16.7. Israel
• 16.8. Italy
• 16.9. Netherlands
• 16.10. Nigeria
• 16.11. Norway
• 16.12. Poland
• 16.13. Qatar
• 16.14. Russia
• 16.15. Saudi Arabia
• 16.16. South Africa
• 16.17. Spain
• 16.18. Sweden
• 16.19. Switzerland
• 16.20. Turkey
• 16.21. United Arab Emirates
• 16.22. United Kingdom

17. Competitive Landscape

• 17.1. Market Share Analysis, 2023
• 17.2. FPNV Positioning Matrix, 2023
• 17.3. Competitive Scenario Analysis
  • 17.3.1. ADx and Alamar Biosciences Partner to enhance neurodegenerative disease biomarker detection
  • 17.3.2. Emery pharma and Marin Biologic partnership to streamline drug development
  • 17.3.3. VION Biosciences expands diagnostic capabilities with strategic acquisition of Ansh Labs
  • 17.3.4. Bio-Rad's launch of SPIA plus transforms specialty immunoassay testing with precision controls
  • 17.3.5. Roche acquires LumiraDx's Point of Care technology platform for sustainable healthcare improvements
  • 17.3.6. Beckman Coulter advances healthcare with new chemistry and immunoassay analyzer
  • 17.3.7. MilliporeSigma and Merck KGaA partneres to enhance research through SMCxPRO immunoassay technology
  • 17.3.8. Beckman Coulter and MeMed strengthen partnership to enhance infection diagnostics
  • 17.3.9. Fujirebio and Agappe partnership for local manufacturing of CLIA based immunoassays
  • 17.3.10. Fujirebio and Sysmex to collaborate on development of unique immunoassays
  • 17.3.11. Shimadzu Corporation invested in IMMUNOSENS Co., Ltd. for implementation of immunoassay technology
  • 17.3.12. Fapon rolls out new chemiluminescence immunoassay system
  • 17.3.13. Beckman Coulter's DxI 9000 immunoassay analyzer with increased assay development sensitivity
  • 17.3.14. Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test
  • 17.3.15. SGS offers enhanced automated immunoassay testing at Poitiers Laboratory
• 17.4. Strategy Analysis & Recommendation
  • 17.4.1. Danaher Corporation
  • 17.4.2. F. Hoffmann-La Roche Ltd.
  • 17.4.3. Siemens Healthineers AG
  • 17.4.4. Thermo Fisher Scientific Inc.

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies Inc.
• 3. Almac Group Limited
• 4. ANP Technologies, Inc.
• 5. Autobio Diagnostics Co., Ltd.
• 6. Becton, Dickinson and Company
• 7. Bio-Rad Laboratories, Inc.
• 8. Bio-Techne Corporation
• 9. BioLegend, Inc.
• 10. bioMerieux S.A.
• 11. Biosurfit SA
• 12. Boditech Med Inc.
• 13. Charles River Laboratories International, Inc.
• 14. Danaher Corporation
• 15. Diasorin S.p.A.
• 16. Dynex Technologies, Inc.
• 17. Epitope Diagnostics Inc.
• 18. F. Hoffmann-La Roche Ltd.
• 19. Fapon Biotech Inc.
• 20. Gyros Protein Technologies AB by Mesa Laboratories, Inc.
• 21. H.U. Group Holdings Inc.
• 22. J. Mitra & Co. Pvt. Ltd.
• 23. Kamiya Biomedical Company
• 24. Koninklijke Philips N.V.
• 25. Merck KGaA
• 26. MiCo BioMed, Inc.
• 27. NanoEntek
• 28. Nanomix, Inc.
• 29. OPKO Health, Inc.
• 30. Promega Corporation
• 31. QIAGEN N.V.
• 32. Quanterix Corporation
• 33. QuidelOrtho Corporation
• 34. Randox Laboratories Ltd.
• 35. Revvity, Inc. (Formarly PerkinElmer, Inc.)
• 36. Sekisui Diagnostics, LLC
• 37. Shenzhen Micropoint Biotechnologies Co., Ltd.
• 38. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 39. Siemens Healthineers AG
• 40. Sysmex Corporation
• 41. Tecan Trading AG
• 42. Thermo Fisher Scientific Inc.
• 43. Tosoh Corporation
• 44. WAK-Chemie Medical GmbH
• 45. Zoetis Inc.
• 46. Zybio Inc.